Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B10 | O60218 | 7/20 | 0.59 |
| ▸ | AKR1B1 | P15121 | 6/20 | 0.59 |
| ▸ | AKR1A1 | P14550 | 2/20 | 0.52 |
| ▸ | CBR1 | P16152 | 2/20 | 0.52 |
| ▸ | AKR1C4 | P17516 | 2/20 | 0.52 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.52 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.52 |
| ▸ | AKR1C1 | Q04828 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | MAOB | P27338 | 3/20 | 0.49 |
| ▸ | ATM | Q13315 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25279702 | 0.89 | AKR1B10 (0.75) | AKR1B10AKR1B1AKR1A1CBR1AKR1C4 | |
| SCHEMBL15298966 | 0.89 | AKR1B10 (0.74) | AKR1B10AKR1B1AKR1A1CBR1AKR1C4 | |
| SCHEMBL25708668 | 0.88 | AKR1B10 (0.77) | AKR1B10AKR1B1AKR1A1CBR1AKR1C4 | |
| SCHEMBL17612195 | 0.86 | ALDH1A1 (0.56) | MEN1MAPTKMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL25235579 | 0.85 | AKR1B10 (0.64) | AKR1B10AKR1B1AKR1A1CBR1AKR1C4 | |
| SCHEMBL13248267 | 0.84 | ALDH1A1 (0.58) | MEN1MAPTKMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL13248272 | 0.83 | ALDH1A1 (0.62) | MEN1MAPTKMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL15298984 | 0.83 | MAOB (0.63) | MEN1MAPTKMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL25239509 | 0.83 | AKR1B10 (0.60) | AKR1B10AKR1B1AKR1A1CBR1AKR1C4 | |
| SCHEMBL13524273 | 0.82 | ALDH1A1 (0.63) | MEN1MAPTKMT2AALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220178934-A1 | SIGNALING CONJUGATES AND METHODS OF USE | VENTANA MED SYST INC (US) | 2022-06-09 | — | — | US | disclosed |
| US-20220021823-A1 | DIGITALLY ENHANCED MICROSCOPY FOR MULTIPLEXED HISTOLOGY | VENTANA MED SYST INC (US) | 2022-01-20 | — | — | US | disclosed |
| US-11070750-B2 | Digitally enhanced microscopy for multiplexed histology | VENTANA MEDICAL SYSTEMS, INC. (US) | 2021-07-20 | — | — | US | disclosed |
| EP-3764083-A1 | DIGITALLY ENHANCED MICROSCOPY FOR MULTIPLEXED HISTOLOGY | Ventana Medical Systems, Inc. (US) | 2021-01-13 | — | — | EP | disclosed |
| EP-3764084-A1 | DIGITALLY ENHANCED MICROSCOPY FOR MULTIPLEXED HISTOLOGY | Ventana Medical Systems, Inc. (US) | 2021-01-13 | — | — | EP | disclosed |
| US-20200358969-A1 | DIGITALLY ENHANCED MICROSCOPY FOR MULTIPLEXED HISTOLOGY | VENTANA MED SYST INC (US) | 2020-11-12 | — | — | US | disclosed |
| US-20200333349-A1 | SIGNALING CONJUGATES AND METHODS OF USE | VENTANA MED SYST INC (US) | 2020-10-22 | — | — | US | disclosed |
| US-20200326345-A1 | SIGNALING CONJUGATES AND METHODS OF USE | VENTANA MED SYST INC (US) | 2020-10-15 | — | — | US | disclosed |
| US-20200319193-A1 | SIGNALING CONJUGATES AND METHODS OF USE | VENTANA MED SYST INC (US) | 2020-10-08 | — | — | US | disclosed |
| US-10778913-B2 | Digitally enhanced microscopy for multiplexed histology | VENTANA MEDICAL SYSTEMS, INC. (US) | 2020-09-15 | — | — | US | disclosed |
| US-20200249238-A1 | SIGNALING CONJUGATES AND METHODS OF USE | VENTANA MED SYST INC (US) | 2020-08-06 | — | — | US | disclosed |
| EP-2972227-B1 | DIGITALLY ENHANCED MICROSCOPY FOR MULTIPLEXED HISTOLOGY | VENTANA MED SYST INC (US) | 2020-05-06 | — | — | EP | disclosed |
| US-10557851-B2 | Signaling conjugates and methods of use | VENTANA MEDICAL SYSTEMS, INC. (US) | 2020-02-11 | — | — | US | disclosed |
| EP-2831587-B1 | SIGNALING CONJUGATES AND METHODS OF USE | VENTANA MED SYST INC (US) | 2018-05-16 | — | — | EP | disclosed |
| US-20140267672-A1 | DIGITALLY ENHANCED MICROSCOPY FOR MULTIPLEXED HISTOLOGY | VENTANA MEDICAL SYSTEMS, INC. | 2014-09-18 | — | — | US | disclosed |
| WO-2014143155-A1 | DIGITALLY ENHANCED MICROSCOPY FOR MULTIPLEXED HISTOLOGY | VENTANA MEDICAL SYSTEMS, INC. (US) | 2014-09-18 | — | — | WO | disclosed |
| EP-2588443-A2 | HAPTEN CONJUGATES FOR TARGET DETECTION | Ventana Medical Systems, Inc. (US) | 2013-05-08 | — | — | EP | disclosed |
| US-20130109019-A1 | HAPTEN CONJUGATES FOR TARGET DETECTION | VENTANA MEDICAL SYSTEMS, INC. | 2013-05-02 | — | — | US | disclosed |
| WO-2012003476-A2 | HAPTEN CONJUGATES FOR TARGET DETECTION | VENTANA MEDICAL SYSTEMS, INC. (US) | 2012-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130109019-A1 | HAPTEN CONJUGATES FOR TARGET DETECTION | TYR, TH, TYRO3 | AKR1B10 1505/4885AKR1B1 1986/4885AKR1A1 2007/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.